TP53 and neoplasm: Furthermore, AURKA has been shown to promote tumor progression and drug resistance by activating oncogenic signaling pathways and inhibiting the key tumor suppressor functions of p53 and TAp73 (Katsha et al., 2017; Wang et al., 2017; Wang-Bishop et al., 2019).